COBAS AMPLIPREP/COBAS TAQMAN HBV TEST

Hepatitis Viral B Dna Detection

FDA Premarket Approval P050028 S004

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for a device design modification that includes reagents, disposables,and instrumentation, to automate the manual sample preparation process currently used by the cobas taqman hbv test for use with the high pure system. The device, as modified,will be marketed under the trade name cobas ampliprep/ cobas taqman hbv test, v2. 0and is indicated for:the cobas ampliprep/cobas taqman hbv test, v2. 0 is an in vitro nucleic acidamplification lest for the quantitation of hepatitis b virus (hbv) dna in human serum orplasma (edta), using the cobas ampliprep instrument for automated specimen processingand the cobas taqman analyzer or cobas taqman 48 analyzer for automatedamplification and detection. This test is intended for use as an aid in the management of patients with chronic hbv infectionundergoing antiviral therapy. The test can be used to measure hbv dna levels at baseline and during treatment to aid in assessing response to treatment. The results from the cobasampliprep/ cobas taqman1 hbv test, v2. 0 must be interpreted within the context of allrelevant clinical and laboratory findings. Assay performance characteristics have been established for individuals treated with adefovirdipivoxil. Assay performance for determining the slate of hbv infection has not been established. The cobas ampliprep/ cobas taqman hbv test, v2. 0 is not intended for use as a screening test for the presence of hbv in blood or blood products or as a diagnostic test toconfirm the presence of hbv infection.

DeviceCOBAS AMPLIPREP/COBAS TAQMAN HBV TEST
Classification NameHepatitis Viral B Dna Detection
Generic NameHepatitis Viral B Dna Detection
ApplicantRoche Molecular Systems, Inc.
Date Received2009-07-01
Decision Date2010-09-09
PMAP050028
SupplementS004
Product CodeMKT
Advisory CommitteeMicrobiology
Supplement TypeNormal 180 Day Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address Roche Molecular Systems, Inc. 4300 Hacienda Drive pleasanton, CA 94588-2722

Supplemental Filings

Supplement NumberDateSupplement Type
P050028Original Filing
S086 2022-10-21 30-day Notice
S085 2021-06-14 30-day Notice
S084 2021-02-23 30-day Notice
S083 2020-07-27 30-day Notice
S082 2020-04-17 30-day Notice
S081 2020-01-23 30-day Notice
S080 2019-10-08 30-day Notice
S079 2019-09-20 30-day Notice
S078 2019-08-16 30-day Notice
S077 2019-07-15 Special (immediate Track)
S076 2019-04-24 30-day Notice
S075 2019-04-08 30-day Notice
S074 2019-03-20 30-day Notice
S073 2018-12-14 30-day Notice
S072 2018-11-13 30-day Notice
S071 2018-11-09 30-day Notice
S070 2018-08-21 30-day Notice
S069 2018-07-27 30-day Notice
S068 2018-06-29 30-day Notice
S067 2018-06-08 30-day Notice
S066 2018-06-04 30-day Notice
S065 2018-05-21 30-day Notice
S064 2018-04-16 30-day Notice
S063 2018-04-16 30-day Notice
S062 2018-04-16 30-day Notice
S061 2018-03-01 30-day Notice
S060 2017-11-14 30-day Notice
S059 2017-10-30 30-day Notice
S058 2017-09-26 30-day Notice
S057 2017-07-14 30-day Notice
S056 2017-07-14 30-day Notice
S055 2017-04-21 Special (immediate Track)
S054 2016-09-22 30-day Notice
S053 2016-07-19 30-day Notice
S052 2016-07-08 30-day Notice
S051 2016-04-18 30-day Notice
S050 2016-04-07 30-day Notice
S049
S048 2015-11-17 Real-time Process
S047 2015-06-24 30-day Notice
S046 2015-04-09 30-day Notice
S045 2015-03-13 30-day Notice
S044 2015-02-25 Real-time Process
S043 2014-12-19 30-day Notice
S042 2014-03-31 30-day Notice
S041 2014-03-18 30-day Notice
S040 2014-02-18 30-day Notice
S039 2013-12-26 30-day Notice
S038 2013-12-13 30-day Notice
S037 2013-09-09 30-day Notice
S036 2013-09-09 30-day Notice
S035 2013-08-14 30-day Notice
S034 2013-08-09 30-day Notice
S033 2013-05-28 30-day Notice
S032 2013-05-09 30-day Notice
S031 2013-04-08 30-day Notice
S030 2013-02-19 Real-time Process
S029 2012-11-16 Real-time Process
S028 2012-11-06 Real-time Process
S027 2012-09-13 30-day Notice
S026 2012-08-15 30-day Notice
S025 2012-05-30 Real-time Process
S024 2012-03-29 Normal 180 Day Track No User Fee
S023 2011-12-12 135 Review Track For 30-day Notice
S022 2011-09-12 30-day Notice
S021 2011-09-01 Special (immediate Track)
S020 2011-07-01 Normal 180 Day Track
S019 2011-05-31 Normal 180 Day Track No User Fee
S018
S017 2011-03-08 135 Review Track For 30-day Notice
S016 2011-03-01 30-day Notice
S015 2011-03-01 135 Review Track For 30-day Notice
S014
S013 2011-02-08 30-day Notice
S012 2010-11-08 30-day Notice
S011 2010-09-22 135 Review Track For 30-day Notice
S010
S009
S008 2010-08-05 30-day Notice
S007 2010-01-08 30-day Notice
S006 2009-12-24 30-day Notice
S005 2009-07-02 30-day Notice
S004 2009-07-01 Normal 180 Day Track
S003 2008-12-05 30-day Notice
S002 2008-10-31 30-day Notice
S001 2008-10-06 Real-time Process

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.